Cochlear shares jump 6% on guidance upgrade

Demand for Cochlear's products has been stronger than expected in FY 2024.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Cochlear Limited (ASX: COH) shares are on the move on Thursday morning.

At the time of writing, the hearing solutions company's shares are up 6% to $310.00.

Two colleagues at work looking at a tablet and smiling at a rising share price.

Image source: Getty Images

Why are Cochlear shares charging higher?

Investors have been fighting to get hold of the company's shares today after it released an update on its guidance for FY 2024.

According to the release, Cochlear has had a stronger than expected first half for cochlear implant revenue and therefore believes it will now outperform its guidance over the full year.

As a reminder, Cochlear was guiding to underlying net profit of $355 million to $375 million for FY 2024.

However, today's update reveals that it is now guiding to underlying net profit in the range of $385 million to $400 million, which will represent a 26% to 31% increase on FY 2023's result.

First half update

While its results will be released in full later this month on 19 February, management has given investors a taste of what's to come.

It advised that it expects to report a first half sales revenue increase of 25% (20% in constant currency) to $1,113 million with underlying net profit of $192 million.

Cochlear's CEO and President, Dig Howitt, commented:

Cochlear implant trading conditions have been strong across the first half, with units growing 14%. We have maintained the market share gains made in FY23 and market growth has continued to be robust across both developed and emerging markets, as well as all age segments – children, adults and seniors. The key change to our expectations is that we now expect to achieve 10-15% growth in our cochlear implant units for FY24 compared to the high single-digit growth expected in August.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Falling pills in a blue background.
Healthcare Shares

Sigma Healthcare shares are surging. What does Macquarie say they're worth?

A possible deal has fallen over, which investors appear to like.

Read more »

Middle age caucasian man smiling confident drinking coffee at home.
Healthcare Shares

CSL shares: bargain or value trap?

Let's see if now is a good time to buy this biotech giant's shares.

Read more »

Three businesswomen collaborate around a table.
Healthcare Shares

Sigma Healthcare withdraws from Boots sale process

The ASX 200 healthcare company cited strategic and capital investment objectives.

Read more »

Young businesswoman sitting in kitchen and working on laptop.
Healthcare Shares

Up 15% in a week, is it too late to buy rebounding CSL shares?

CSL shares trade on roughly 13 times forecast FY26 earnings and offer a good dividend yield.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Broker Notes

Down 60%, are Cochlear shares now a bargain buy?

A leading analyst provides his outlook for Cochlear’s beaten-down shares.

Read more »

Young woman thinking with laptop open.
Healthcare Shares

Why are Sigma Healthcare shares in the spotlight this week?

Is the latest sell-off overdone?

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Is it time to get greedy with Pro Medicus shares?

The company was swept up in the huge sector-wide downturn in late 2025 and early 2026 as investors turned their…

Read more »

Young doctor raising arms in air with hands in fists celebrating a new development.
Healthcare Shares

Prediction: I think Telix shares could double in value in 2026. Here's why

The biopharmaceutical company's shares dipped to a three-year low in February, but have now rebounded strongly.

Read more »